Cargando…

Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate

To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Boschheidgen, M., Schimmöller, L., Doerfler, S., Al-Monajjed, R., Morawitz, J., Ziayee, F., Mally, D., Quentin, M., Arsov, C., Albers, P., Antoch, G., Ullrich, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038748/
https://www.ncbi.nlm.nih.gov/pubmed/35469056
http://dx.doi.org/10.1038/s41598-022-10859-9
_version_ 1784693971117670400
author Boschheidgen, M.
Schimmöller, L.
Doerfler, S.
Al-Monajjed, R.
Morawitz, J.
Ziayee, F.
Mally, D.
Quentin, M.
Arsov, C.
Albers, P.
Antoch, G.
Ullrich, T.
author_facet Boschheidgen, M.
Schimmöller, L.
Doerfler, S.
Al-Monajjed, R.
Morawitz, J.
Ziayee, F.
Mally, D.
Quentin, M.
Arsov, C.
Albers, P.
Antoch, G.
Ullrich, T.
author_sort Boschheidgen, M.
collection PubMed
description To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI (T2WI, DWI, DCE) and subsequent MRI-targeted and systematic TRUS-guided biopsy between 2012 and 2018. Primary study objective was the verification of a significant PI-RADS category upgrade in follow-up mpMRI in patients with subsequent PCA positive biopsy versus patients with negative biopsy. Further objectives were development of the PI-RADS category and clinical parameters between initial and follow-up mpMRI in the context of histopathologic results and time interval. Eighty-nine patients (median PSA 6.6 ng/ml; PSAD 0.13 ng/ml/ml) were finally included (follow-up period 31 ± 18 months). 19 cases had PCA (median PSA 7.8 ng/ml; PSAD 0.14 ng/ml/ml). 4 cases had csPCA (median PSA 5.4 ng/ml; PSAD 0.13 ng/ml/ml) for which there was a significant PI-RADS upgrade after 12–24 months (mean 3.75; p = 0.01) compared to patients without PCA (mean 2.74). Without PCA the mean PI-RADS category decreased after 25–36 months (mean 2.74; p = 0.02). Clinical parameters did not change significantly except a PSAD increase for PCA patients after 24 months. Patients within PI-RADS category 3 may not need prompt biopsy since those with PCA reliably demonstrate a PI-RADS category upgrade in follow-up mpMRI after 12–24 months. PI-RADS 3 patients with negative biopsy do not benefit from follow-up mpMRI earlier than 24 months.
format Online
Article
Text
id pubmed-9038748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90387482022-04-27 Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate Boschheidgen, M. Schimmöller, L. Doerfler, S. Al-Monajjed, R. Morawitz, J. Ziayee, F. Mally, D. Quentin, M. Arsov, C. Albers, P. Antoch, G. Ullrich, T. Sci Rep Article To evaluate if follow-up mpMRI scans of patients in PI-RADS category 3 are safe enough to omit or delay prostate biopsy in the future and to determine an optimal control interval. This retrospective single center study includes consecutive PI-RADS category 3 patients with one or more follow-up mpMRI (T2WI, DWI, DCE) and subsequent MRI-targeted and systematic TRUS-guided biopsy between 2012 and 2018. Primary study objective was the verification of a significant PI-RADS category upgrade in follow-up mpMRI in patients with subsequent PCA positive biopsy versus patients with negative biopsy. Further objectives were development of the PI-RADS category and clinical parameters between initial and follow-up mpMRI in the context of histopathologic results and time interval. Eighty-nine patients (median PSA 6.6 ng/ml; PSAD 0.13 ng/ml/ml) were finally included (follow-up period 31 ± 18 months). 19 cases had PCA (median PSA 7.8 ng/ml; PSAD 0.14 ng/ml/ml). 4 cases had csPCA (median PSA 5.4 ng/ml; PSAD 0.13 ng/ml/ml) for which there was a significant PI-RADS upgrade after 12–24 months (mean 3.75; p = 0.01) compared to patients without PCA (mean 2.74). Without PCA the mean PI-RADS category decreased after 25–36 months (mean 2.74; p = 0.02). Clinical parameters did not change significantly except a PSAD increase for PCA patients after 24 months. Patients within PI-RADS category 3 may not need prompt biopsy since those with PCA reliably demonstrate a PI-RADS category upgrade in follow-up mpMRI after 12–24 months. PI-RADS 3 patients with negative biopsy do not benefit from follow-up mpMRI earlier than 24 months. Nature Publishing Group UK 2022-04-25 /pmc/articles/PMC9038748/ /pubmed/35469056 http://dx.doi.org/10.1038/s41598-022-10859-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Boschheidgen, M.
Schimmöller, L.
Doerfler, S.
Al-Monajjed, R.
Morawitz, J.
Ziayee, F.
Mally, D.
Quentin, M.
Arsov, C.
Albers, P.
Antoch, G.
Ullrich, T.
Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title_full Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title_fullStr Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title_full_unstemmed Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title_short Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate
title_sort single center analysis of an advisable control interval for follow-up of patients with pi-rads category 3 in multiparametric mri of the prostate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038748/
https://www.ncbi.nlm.nih.gov/pubmed/35469056
http://dx.doi.org/10.1038/s41598-022-10859-9
work_keys_str_mv AT boschheidgenm singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT schimmollerl singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT doerflers singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT almonajjedr singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT morawitzj singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT ziayeef singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT mallyd singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT quentinm singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT arsovc singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT albersp singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT antochg singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate
AT ullricht singlecenteranalysisofanadvisablecontrolintervalforfollowupofpatientswithpiradscategory3inmultiparametricmrioftheprostate